title: [Tolerability in ophthalmologic surgery of CY 216 in preventing venous thrombosis of the leg].
abstract: The specificity of the action of low-molecular-weigh heparin promotes its prevention use in ophthalmological surgery, where any hemorrhage, even if not of vital consequence, can reduce and even cancel out the results of the surgery. Consequently, we subjected 63 patients (21 male, 42 female) aged 54 to 93 to preventive treatment with Fraxiparine (CY 216) as per the conventional indications of risk factors: essentially venous insufficiency [23], varicose veins [29], a history of phlebitis [20] or pulmonary embolism [12]. A first group of 31 patients (protocol P 1) was given the first injection 2 hours prior to surgery (D 0). A second group of 32 patients (P 2) was given the injection at 10 p.m. on the eve of surgery (D-1). P 1 and P 2 were given CY 216 (0.3 ml, one injection at 6 a.m.) each day from D 1 to D 7 (and 7 patients from P 1 until D 10). The type of surgery concerned was: cataract [46], retinal detachment [11], glaucoma [3]; fifteen patients had already undergone surgery and 6 were given CY 216 twice. P 2 was compared with a control group T of 20 patients (7 male, 13 females, mean age 71.8) in the same department given calcium heparin sc (3 x 0.2 ml daily, D 1 to D 7). In P 1 and P 2, as well as in the T group, no clinical thromboembolic complications were observed. Tolerance, however, differed. In P 1: 2 cases of hyphema and one of choroidal hematoma. In P 2: no significant hemorrhage.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Médecine interne, CHNO des Quinze-Vingts, Paris.
authors.forename: Y
authors.initials: Y
authors.lastname: Morin
authors.forename: S
authors.initials: S
authors.lastname: Limon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005128:Eye Diseases / Q000601:surgery; D005130:Eye Hemorrhage / Q000139:chemically induced; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011446:Prospective Studies; D012307:Risk Factors; D013924:Thrombophlebitis / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight
vernacular_title: Etude de la tolérance en chirurgie ophtalmologique du CY 216 employépour la prévention des thromboses veineuses des membres inférieurs.